Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

New Targets Found That Stop Tumor Growth

Blocking blood vessel formation has already worked against breast, colon cancers

FRIDAY, May 2 (HealthDay News) -- A number of potential new targets for treatments that block tumor blood vessel formation -- a key step in tumor growth and metastasis -- have been identified by researchers at the University of North Carolina at Chapel Hill.

The use of the drug bevacizumab (Avastin) to target the formation of blood vessels (angiogenesis) that feed tumors has proven successful in treating breast and colon cancer, according to background information in the study. The drug inhibits a protein called vascular endothelial growth factor (VEGF), which plays a major role in angiogenesis.

Related Stories
No Evidence Breast Self-Exams Cut Cancer Deaths
Recent Genetic Discoveries Don't Improve Prediction of Breast Cancer
Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed
Related Videos
Gene Test for Chemo
The Women Behind the Pink Ribbon
Preventing Breast Cancer
Related Slides
Breast Cancer
Breast Self-Exam

"There is a large amount of data that shows if you block angiogenesis, you can block tumor growth. But VEGF is not responsible for all of angiogenesis. We wanted to identify more targets for this therapeutic approach," study senior author Dr. Nancy Klauber-DeMore, an associate professor of surgery in the UNC School of Medicine, said in a prepared statement.

She and her colleagues identified new targets after analyzing blood vessel cells in cancerous and normal breast tissue samples. They identified 1,176 genes that differed in activity or expression between the two cell populations. Of those, 55 genes were overexpressed more than fourfold in blood vessels from breast cancer.

"The most exciting aspect of this study is that we now have a very large list of potential targets that we will continue to work on for at least the next decade," Klauber-DeMore said.

So far, she and her colleagues have only looked at seven out of the 55 potential targets.

"This work points us in the direction we need to go to develop the next generation of angiogenesis inhibitors," Klauber-DeMore said.

The study was published in the current issue of The American Journal of Pathology.

More information

The U.S. National Cancer Institute has more about angiogenesis.

-- Robert Preidt

SOURCE: University of North Carolina at Chapel Hill, news release, April 23, 2008

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/2/2008

Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.

Jul 25, 2008
Powered By HealthLine
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
verify here.
About The HealthScout Network Contact Us
Copyright 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: